Prokidney

PROK · NASDAQ

$1.44+$0.045 (+3.23%)TodayMarket closed · Oct 20, 7:43 PM ET

Prev close $1.40

PROK analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $6.38 (+342.7% upside)

Low: $1.01
Now: $1.44
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

PROK analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	May 18, 2026	Maintains	Buy	$12.00	40%
HC Wainwright & Co.	Dec 16, 2025	Initiates	Buy	$12.00	40%

The case for and against

Updated Jun 3, 2026

Bull case

ProKidney is a clinical-stage biotechnology company developing a revolutionary autologous cell therapy, REACT, for patients with advanced chronic kidney disease (CKD) and diabetes. With positive Phase 3 trial results and acceptance of the therapy by the FDA, ProKidney's stock has a positive outlook, potentially leading to future sales and profitability. The company's diverse pipeline also includes the exploration of REACT's potential for non-diabetic CKD patients. Overall, ProKidney has a promising future in the treatment of chronic kidney disease, making it a potentially valuable investment opportunity for financial analysts.

Bear case

ProKidney is a clinical-stage biotechnology company that specializes in developing a first-in-class, autologous cell therapy for the treatment of chronic kidney disease (CKD) and diabetes. However, their product candidate, REACT, has yet to demonstrate significant clinical success, and there are already established pharmaceutical companies with similar, if not more advanced, therapies in development for CKD. Additionally, the company's financials suggest a high risk for future funding and their pipeline is limited to one asset, which could impede their ability to create significant shareholder value in the long term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.